Aponvie Emulsion
NDC Package 47426-401-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Aponvie (aprepitant) emulsions is aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). This formulation utilizes a emulsion delivery system. Marketed by Heron Therapeutics, Inc., this product is identified by NDC 47426-401 and is authorized under FDA application NDA216457.

Identification & Billing

NDC Package Code
47426-401-10
Package Description
10 VIAL, GLASS in 1 CARTON / 4.4 mL in 1 VIAL, GLASS (47426-401-01)
Product Code
47426-401
11-Digit Billing Format
47426040110
Billing Unit
C112160
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Aponvie
Non-Proprietary Name
Aprepitant
Substance Name
Aprepitant
Dosage Form
Emulsion - A dosage form consisting of a two-phase system comprised of at least two immiscible liquids1, one of which is dispersed as droplets (internal or dispersed phase) within the other liquid (external or continuous phase), generally stabilized with one or more emulsifying agents. (Note: Emulsion is used as a dosage form term unless a more specific term is applicable, e.g. cream, lotion, ointment.)
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
APREPITANT 32 mg/4.4mL
Pharmacologic Class
Usage Information
Aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Aprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

Regulatory & Marketing

Labeler Name
Heron Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA216457
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-06-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J8502
Source: ASP
Inj, aponvie, 1 mg
HCPCS Dosage 1 MG
Units / Pkg 320

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 47426-401-10 identifies a specific commercial package of 10 vial, glass in 1 carton / 4.4 ml in 1 vial, glass (47426-401-01) of Aponvie, a human prescription drug labeled by Heron Therapeutics, Inc.. This emulsion is formulated for intravenous use and contains aprepitant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Heron Therapeutics, Inc. on March 06, 2023. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Aprepitant is used with other medications to help prevent nausea and vomiting caused by cancer drug treatment (chemotherapy). Aprepitant works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This medication will not treat nausea or vomiting that has already started. Ask your doctor what you should do if you already have nausea or vomiting.

How is this Heron Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 47426040110. Quantities are measured in C112160. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
47426-401-10
11-Digit CMS (5-4-2)
47426-0401-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.